115 related articles for article (PubMed ID: 8371583)
1. Characterization of circulating erythrocytes from myelodysplastic patients treated with recombinant human erythropoietin.
Shapiro S; Gershon H; Rosenbaum H; Merchav S
Leukemia; 1993 Sep; 7(9):1328-33. PubMed ID: 8371583
[TBL] [Abstract][Full Text] [Related]
2. Prediction of response to treatment with human recombinant erythropoietin in myelodysplastic syndromes.
Stenke L; Wallvik J; Celsing F; Hast R
Leukemia; 1993 Sep; 7(9):1324-7. PubMed ID: 8371582
[TBL] [Abstract][Full Text] [Related]
3. Weekly standard doses of rh-EPO are highly effective for the treatment of anemic patients with low-intermediate 1 risk myelodysplastic syndromes.
Balleari E; Clavio M; Arboscello E; Bellodi A; Bruzzone A; Del Corso L; Lucchetti MV; Miglino M; Passalia C; Pierri I; Ponassi I; Oneto C; Racchi O; Scudeletti M; Vignolo L; Zoppoli G; Gobbi M; Ghio R
Leuk Res; 2011 Nov; 35(11):1472-6. PubMed ID: 21794914
[TBL] [Abstract][Full Text] [Related]
4. Recombinant human erythropoietin for treatment of myelodysplastic syndromes.
Rafanelli D; Grossi A; Longo G; Vannucchi AM; Bacci P; Ferrini PR
Leukemia; 1992 Apr; 6(4):323-7. PubMed ID: 1588794
[TBL] [Abstract][Full Text] [Related]
5. Erythropoietin plus granulocyte colony-stimulating factor is better than erythropoietin alone to treat anemia in low-risk myelodysplastic syndromes: results from a randomized single-centre study.
Balleari E; Rossi E; Clavio M; Congiu A; Gobbi M; Grosso M; Secondo V; Spriano M; Timitilli S; Ghio R
Ann Hematol; 2006 Mar; 85(3):174-80. PubMed ID: 16408206
[TBL] [Abstract][Full Text] [Related]
6. In vitro studies of erythropoietin-dependent regulation of erythropoiesis in myelodysplastic syndromes.
Merchav S; Nielsen OJ; Rosenbaum H; Sharon R; Brenner B; Tatarsky I; Scigalla P; Wieczorek L
Leukemia; 1990 Nov; 4(11):771-4. PubMed ID: 2232891
[TBL] [Abstract][Full Text] [Related]
7. Pathophysiological aspects of red blood cells in end-stage renal disease patients resistant to recombinant human erythropoietin therapy.
Georgatzakou HT; Tzounakas VL; Kriebardis AG; Velentzas AD; Papageorgiou EG; Voulgaridou AI; Kokkalis AC; Antonelou MH; Papassideri IS
Eur J Haematol; 2017 Jun; 98(6):590-600. PubMed ID: 28295628
[TBL] [Abstract][Full Text] [Related]
8. Subcutaneous recombinant human erythropoietin for the treatment of anemia in myelodysplastic syndromes.
Ghio R; Balleari E; Ballestrero A; Gatti AM; Mareni C; Massa G; Patrone F; Sessarego M; Timitilli S
Acta Haematol; 1993; 90(2):58-64. PubMed ID: 8285019
[TBL] [Abstract][Full Text] [Related]
9. Successful treatment of refractory anemia with a combination regimen containing recombinant human erythropoietin, low-dose methylprednisolone and nandrolone.
Tsiara SN; Chaidos A; Gouva M; Christou L; Panteli K; Kapsali E; Bourantas KL
J Exp Clin Cancer Res; 2004 Mar; 23(1):47-52. PubMed ID: 15149150
[TBL] [Abstract][Full Text] [Related]
10. Treatment of MDS patients with recombinant human erythropoietin and the role of GSTs.
Tsabouri SE; Georgiou I; Katsaraki A; Bourantas KL
J Exp Clin Cancer Res; 2004 Sep; 23(3):417-24. PubMed ID: 15595630
[TBL] [Abstract][Full Text] [Related]
11. Recognition and sequestration of young and old erythrocytes from young and elderly human donors: in vitro studies.
Sheiban E; Gershon H
J Lab Clin Med; 1993 Mar; 121(3):493-501. PubMed ID: 8445298
[TBL] [Abstract][Full Text] [Related]
12. Modifications of erythropoiesis in myelodysplastic syndromes treated with recombinant erythropoietin as evaluated by soluble transferrin receptor, high fluorescence reticulocytes and hypochromic erythrocytes.
Musto P; Modoni S; Alicino G; Savino A; Longo A; Bodenizza C; Falcone A; D'Arena G; Scalzulli P; Perla G
Haematologica; 1994; 79(6):493-9. PubMed ID: 7896207
[TBL] [Abstract][Full Text] [Related]
13. Response to recombinant human erythropoietin in patients with myelodysplastic syndromes.
Stasi R; Brunetti M; Bussa S; Conforti M; Di Giulio C; Crescenzi A; Terzoli E; Vecchione A; Pagano A
Clin Cancer Res; 1997 May; 3(5):733-9. PubMed ID: 9815743
[TBL] [Abstract][Full Text] [Related]
14. Recombinant human erythropoietin in the treatment of myelodysplastic syndromes. An interim report.
Aloe Spiriti MA; Petti MC; Latagliata R; Avvisati G; De Gregoris C; Proia S; Fazi P; Jaalouk G; Mancini M; Spadea A
Haematologica; 1993; 78(2):123-6. PubMed ID: 8349188
[TBL] [Abstract][Full Text] [Related]
15. Serum erythropoietin level and marrow erythroid infiltration predict response to recombinant human erythropoietin in myelodysplastic syndromes.
Depaoli L; Levis A; Isabella N; Ficara F; Priotto C; Lista P; Foà R; Resegotti L
Haematologica; 1993; 78(2):118-22. PubMed ID: 8349187
[TBL] [Abstract][Full Text] [Related]
16. Recombinant human erythropoietin in the treatment of myelodysplastic syndromes--response patterns.
Lewinski UH; Floru S; Cohen AM; Mittelmann M
Leuk Lymphoma; 1994 Sep; 15(1-2):149-52. PubMed ID: 7858493
[TBL] [Abstract][Full Text] [Related]
17. Serum levels of tumour necrosis factor-alpha predict response to recombinant human erythropoietin in patients with myelodysplastic syndrome.
Stasi R; Brunetti M; Bussa S; Conforti M; Martin LS; La Presa M; Bianchi M; Parma A; Pagano A
Clin Lab Haematol; 1997 Sep; 19(3):197-201. PubMed ID: 9352145
[TBL] [Abstract][Full Text] [Related]
18. Recombinant human erythropoietin in patients with myelodysplastic syndromes.
Schouten HC; Vellenga E; van Rhenen DJ; de Wolf JT; Coppens PJ; Blijham GH
Leukemia; 1991 May; 5(5):432-6. PubMed ID: 2033964
[TBL] [Abstract][Full Text] [Related]
19. Effect of membrane-bound IgG and desialysation in the interaction of monocytes with senescent erythrocytes.
Ensinck A; Biondi CS; Marini A; García Borrás S; Racca LL; Cotorruelo CM; Racca AL
Clin Exp Med; 2006 Oct; 6(3):138-42. PubMed ID: 17061064
[TBL] [Abstract][Full Text] [Related]
20. Erythropoietin plus granulocyte colony-stimulating factor in the treatment of myelodysplastic syndromes. Identification of a subgroup of responders. The Spanish Erythropathology Group.
Remacha AF; Arrizabalaga B; Villegas A; Manteiga R; Calvo T; Julià A; Fernández Fuertes I; González FA; Font L; Juncà J; del Arco A; Malcorra JJ; Equiza EP; de Mendiguren BP; Romero M
Haematologica; 1999 Dec; 84(12):1058-64. PubMed ID: 10586205
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
